Rani Therapeutics HoldingsRANI +0.69%32 Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 151 Biotechnology companies, Rani Therapeutics Holdings ranks worse than 662250.99% on this metric.
The historical rank and industry rank for Rani Therapeutics Holdings's Dividend Yield % or its related term are showing as below:
RANI's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.53 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RANI vs CGTX, INO, ALDX: Dividend Yield % Comparison
For the Biotechnology subindustry, Rani Therapeutics Holdings's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rani Therapeutics Holdings Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Rani Therapeutics Holdings's Dividend Yield % falls into.
Rani Therapeutics Holdings (RANI) has a Dividend Yield % of 0.00% as of Jun. 26, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Rani Therapeutics Holdings and its competitors. According to the industry distribution chart, Rani Therapeutics Holdings ranks #999999 out of 151 companies in the Biotechnology industry.
Is Rani Therapeutics Holdings' Dividend Yield % too high?
Rani Therapeutics Holdings' current Dividend Yield % is 0.00%. Based on the distribution chart, Rani Therapeutics Holdings ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Rani Therapeutics Holdings' Dividend Yield % compare to CGTX and INO?
According to the Biotechnology industry distribution chart, Rani Therapeutics Holdings ranks #999999 out of 151 companies for Dividend Yield %. This places Rani Therapeutics Holdings in the lower half of its industry. The industry median Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Rani Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rani Therapeutics Holdings's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rani Therapeutics Holdings stock overvalued right now?
Rani Therapeutics Holdings (RANI) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
32GF Score
Get the complete analysis for RANI
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RANI has been successfully added to your 
